CNTN4抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10217(CNTN4 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10217(CNTN4 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The CNTN4 antibody targets Contactin-4 (CNTN4), a cell adhesion molecule belonging to the immunoglobulin superfamily. CNTN4 is primarily expressed in the nervous system and plays critical roles in neural development, including axon guidance, synapse formation, and neuronal network plasticity. It interacts with extracellular matrix components and other cell surface proteins, such as amyloid precursor protein (APP), to mediate cell-cell adhesion and signaling. Genetic studies have linked CNTN4 to neurodevelopmental disorders, including autism spectrum disorder (ASD) and schizophrenia, highlighting its potential involvement in brain function and pathology.

CNTN4 antibodies are essential tools for studying the protein’s expression, localization, and function in both physiological and disease contexts. They are widely used in techniques like immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to visualize CNTN4 distribution in tissues, particularly the brain. Researchers also utilize these antibodies to investigate CNTN4’s role in animal models of neurological diseases or to validate CRISPR/Cas9-mediated gene knockout efficiency. Commercially available CNTN4 antibodies include monoclonal and polyclonal variants, often validated for specificity using knockout controls. Challenges in antibody development include minimizing cross-reactivity with other Contactin family members (e.g., CNTN1-3. CNTN5-6) due to structural homology. Proper validation and application of CNTN4 antibodies remain crucial for advancing research into its biological significance and therapeutic potential.